2-dehydrosparteine: urinary metabolite of sparteine; RN given refers to (7S-(7alpha,7aalpha,14alpha,14beta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2,3-didehydrosparteine : A quinolizidine alkaloid obtained by formal dehydrogenation at the 2,3-position of sparteine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 3035890 |
| CHEBI ID | 29130 |
| SCHEMBL ID | 79296 |
| MeSH ID | M0130374 |
| Synonym |
|---|
| (7s,7ar,14r,14as)-1,3,4,7,7a,8,9,13,14,14a-decahydro-7,14-methano-2h,6h-dipyrido[1,2-a:1',2'-e][1,5]diazocine |
| 2,3-didehydrosparteine |
| CHEBI:29130 |
| 67528-17-0 |
| 2-dehydrosparteine |
| inchi=1/c15h24n2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h3,7,12-15h,1-2,4-6,8-11h2/t12?,13?,14-,15-/m0/s |
| 7,14-methano-2h,6h-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, 1,3,4,7,7a,8,9,13,14,14a-decahydro-, (7s-(7alpha,7aalpha,14alpha,14abeta))- |
| SCHEMBL79296 |
| DTXSID40986910 |
| Q27109957 |
| (1s,2r,9s,10s)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadec-5-ene |
| Excerpt | Reference | Relevance |
|---|---|---|
| " and the pharmacokinetic parameters were estimated." | ( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To establish the bioavailability of tropisetron (5 mg) administered orally as capsule compared with 2 mg given intravenously." | ( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001) | 0.31 |
| "Tropisetron exhibits a wide range of oral bioavailability at therapeutic doses, which is mainly determined by CYP2D6 activity." | ( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001) | 0.31 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Of the 141 subjects dosed with debrisoquin, 10 proved to be poor oxidizers, and of the 143 subjects dosed with phenformin, 11 were poor oxidizers." | ( Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Eichelbaum, M; Idle, JR; Oates, NS; Smith, RL; Woolhouse, NM, 1985) | 0.27 |
| Class | Description |
|---|---|
| quinolizidine alkaloid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (58.33) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||